Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Stewart B Harris, Kamlesh Khunti, Mona Landin-Olsson, Claus B Galbo-Jørgensen, Mette Bøgelund, Barrie Chubb, Jens Gundgaard & Marc Evans. (2013) Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective. Patient Preference and Adherence 7, pages 925-936.
Read now
Read now
Robert Deuson, Mark Danese, Susan D. Mathias, Marieke Schoonen & Jon Fryzek. (2012) The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim. Journal of Medical Economics 15:5, pages 956-976.
Read now
Read now
M. Iskedjian, A. T. Tinmouth, D. M. Arnold, R. Deuson, J. J. Isitt & J. Mikhael. (2012) Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue. Journal of Medical Economics 15:2, pages 313-331.
Read now
Read now
Articles from other publishers (9)
Mingjun Rui, Yingcheng Wang, Zhengyang Fei, Ye Shang, Aixia Ma & Hongchao Li. (2021) Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China. Frontiers in Medicine 8.
Crossref
Crossref
Mark Oremus, Anis Sharafoddini, Gian Paolo Morgano, Xuejing Jin & Feng Xie. (2018) A Computer-Assisted Personal Interview App in Research Electronic Data Capture for Administering Time Trade-off Surveys (REDCap): Development and Pretest. JMIR Formative Research 2:1, pages e3.
Crossref
Crossref
Vasilii Anatol'evich Shuvaev, S.V. Voloshin, A.K. Hadzhidis & A.V. Chechetkin. (2017) Pharmacoeconomic Analysis of the Use of Thrombopoietin Receptors Agonists in Idiopathic Thrombocytopenic Purpura Therapy. Clinical oncohematology 10:4, pages 435-442.
Crossref
Crossref
Rachel Allen, Peter Bryden, Kelly M. Grotzinger, Ceilidh Stapelkamp & Bethan Woods. (2016) Cost-Effectiveness of Eltrombopag versus Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in England and Wales. Value in Health 19:5, pages 614-622.
Crossref
Crossref
Jean Lachaine, Karine Mathurin, Stéphane Barakat & Stephen Couban. (2015) Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada. European Journal of Haematology 95:3, pages 218-229.
Crossref
Crossref
Dawn Lee, Patrick Thornton, Alexander Hirst, Lucie Kutikova, Robert Deuson & Nic Brereton. (2013) Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland. Applied Health Economics and Health Policy 11:5, pages 457-469.
Crossref
Crossref
Marc Evans, Kamlesh Khunti, Muhammad Mamdani, Claus B Galbo-Jørgensen, Jens Gundgaard, Mette Bøgelund & Stewart Harris. (2013) Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health and Quality of Life Outcomes 11:1, pages 90.
Crossref
Crossref
Javier Soto ÁlvarezJavier Soto Álvarez. 2012. Evaluación económica de medicamentos y tecnologías sanitarias:. Evaluación económica de medicamentos y tecnologías sanitarias:
105
125
.
Miguel A. Sanz, Louis Aledort, Susan D. Mathias, Xuena Wang & John J. Isitt. (2011) Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value in Health 14:1, pages 90-96.
Crossref
Crossref